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ABSTRACT 
Objectives: To assess the factors affecting stem cell 
mobilization in patients treated with hematopoietic 
peripheral stem cell transplantation.  
Patients and Methods: Autologous bone marrow 
transplants in 143 patients with 169 stem cell harvesting 
procedures were analysed retrospectively.  
Results: Stem cell mobilization was done with Filgrastim 
in 89 patients (52.7 %) and with Lenograstim in 80 
patients (47.3%). For stem cell harvesting, Fresenius 
apheresis device was used in 69 patients (40.8%), while 
Haemonetics apheresis device was used in 100 patients 
(59.2%). In univariate analysis, patient’s diagnosis 
(p=0.005), number of treatment lines before the apheresis 
procedure (p=0.0004), number of leukocytes and CD34+ 
cell count at the first day of the apheresis procedure 
(p=0.0001 and p=0.0005, respectively), mobilization with 
filgrastim (p=0.00004) and mobilization with the Fresenius 
apheresis device (p=0.007) were statistically significant. 
In multivariate analysis, diagnosis of the patient (p=0.01), 
mobilization with filgrastim (p= 0.001), mobilization with 
Fresenius apheresis device (p=0.03), and leukocyte 
count at first day of apheresis (p=0.006) were important 
factors affecting peripheral stem cell mobilization. 
Conclusion: Patient’s diagnosis, mobilization with 
filgrastim and Fresenius apheresis device, peripheral 
blood leukocyte count at the first day of apheresis seem 
to be important in affecting peripheral stem cell 
mobilization. 
Keywords: Stem cell mobilization, Hematopoietic 
peripheral stem cell transplantation, Filgrastim, 
Lenograstim, Apheresis 
ÖZET
Amaç: Otolog kök hücre transplantasyonunun başarısı 
yeterli sayıda kök hücrenin infüzyonuna bağlıdır. Bu 
nedenle kök hücre mobilizasyonunu etkileyen faktörlerin 
tanımlanması önem taşımaktadır. Çalışmamızın amacı, 
otolog kök hücre nakli uygulanan hastalarda kök hücre 
mobilizasyonunu etkileyen faktörleri belirlemektir.    
Hastalar ve Yöntemler: Otolog kök hücre nakli yapılan 
143 hasta ve bu hastalara uygulanan 169 kök hücre 
aferez işlemi retrospektif olarak değerlendirildi. 
Bulgular: Kök hücre mobilizasyonu için 89 (%52.7) 
hastada Filgrastim, 80 (%47.3) hastada Lenograstim 
kullanıldı. Aferez işleminde 69 (%40.8) hastada 
Fresenius, 100 (%59.2) hastada Haemonetics cihazı 
kullanıldı. Tek değişkenli analizlerde tanı (p=0.005), 
aferez öncesi tedavi sayısı (p:0.0004), tanıdan afereze 
kadar geçen süre (p:0.02), aferezin 1. günündeki lökosit 
ve CD34+ hücre sayısı (p:0.0001; p:0.0005), filgrastim 
kullanımı (p=0.00004) ve fresenius cihazının kullanımı 
(p:0.007)’nın kök hücre mobilizasyonunu etkileyen 
faktörler olduğu görüldü. Çok değişkenli analizlerde ise 
en önemli faktörlerin tanı (p=0.01), filgrastim kullanımı 
(p=0.001), fresenius cihazının kullanımı (p=0.03) ve 
aferezin 1. günündeki lökosit sayısı (p=0.006) olduğu 
saptandı. 
Sonuç: Çalışmamızda tanı, filgrastim ile mobilizasyon, 
fresenius cihazının kullanılması, ve aferezin 1. gününde 
periferik kandaki WBC sayısının kök hücre 
mobilizasyonunu etkileyen en önemli değişkenler olduğu 
saptanmıştır. 
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Hematopoetik periferal kök hücre nakli, Filgrastim, 
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High dose chemotherapy, followed by 
autologous bone marrow transplantation is used 
widely in the treatment of hematological and some 
non-hematological solid tumors. New developments 
in transplantation medicine have broadened its 
usage. For a successful autologous bone marrow 
transplantation and a rapid, stable hematological 
reconstitution, infusion of a sufficent number and 
adequate quality of stem cells is necessary. In 
previous clinical trials, it has been postulated that, 
infusion of 2x106 cells/kg of CD34+ stem cells is 
minimally sufficient for a safe neutrophil and 
thrombocyte engraftment at day 14 after the 
transplantation. The transfer of hematopoietic 
progenitor cells (HPCs) from bone marrow to the 
peripheral blood is called mobilization. Nowadays, 
peripherally mobilized stem cells is the preferred 
method over direct bone marrow harvesting for 
autologous bone marrow transplantation. Higher 
rates of cell collection, faster engraftment, lower 
rates of procedural complications, easier 
accesibility, lower rates of tumor contamination and 
faster hematopoietic and immune reconstitution are 
the attributed causes of this situation1-3. Because 
successful autologous bone marrow transplantation 
is strictly related to the infused quality and number 
of stem cells, various studies have investigated the 
factors affecting stem cell mobilization and the 
causes of inadequate mobilization. Many factors 
affecting stem cell mobilization have been reported, 
previously. Diagnosis of the patient, chemotherapies 
applied and number of therapy lines before 
autologous transplantation, number of relapses, 
growth factors used for mobilization, type of 
apheresis devices used, leukocyte and CD34+ cell 
count at the first day of apheresis can all affect the 
success of stem cell mobilization. Several studies 
have reported distinct and controversial results 
about these factors. The reason for this disparity 
can be attributed to small sample size, inclusion of 
different heterogenous mobilization protocols to the 
analysis or the absence of exact criteria for 
unsuccessful mobilization. The purpose of this study 
is to evaluate the factors affecting stem cell 
mobilization in patients treated with high dose 
therapy followed by hematopoietic peripheral stem 
cell rescue. 
PATIENTS and  METHODS 
In this study we retrospectively analysed 
154 patients treated with autologous bone marrow 
transplantation between the years 1993 and 2010, 
followed at the Bone Marrow Transplantation Unit, 
Hematology Division, Marmara University Hospital. 
A total of 180 harvesting procedures were applied. 
In eleven cases, harvesting was done from bone 
marrow and these cases were excluded from the 
study. One hundered and fortythree patients and 
169 apheresis procedures for peripheral stem cell 
harvesting were analysed. Daily apheresis was 
performed using continuous flow blood cell 
separators of the companies Fresenius or 
Haemonetecs. Median age was 48 (range 18-66). 
Eighty one (56.6%) patients were male, 62 (43.4%) 
patients were female. For the 143 patients 
analysed, the diagnoses were: multiple myeloma in 
67 patients (46.9%), acute leukemia in 11 patients 
(7.7%), Hodgkin’s Disease in 31 patients (21.7%), 
non-Hodgkin’s lymphoma in 33 patients (23.1%) and 
a solid tumor in only one patient (0.7%). Before the 
apheresis procedure, the median number of disease 
relapse was one (range 0-5), the median  number of 
treatment lines received was two (range 1-6); the 
median time between the diagnosis to the apheresis 
procedure was 13 months (range 1-228). Fortythree 
patients (30.1%) received involved field radiation 
therapy before the apheresis procedure. For stem 
cell mobilization, Filgrastim was used in 89 patients 
(52.7%) while Lenograstim was used in 80 (47.3%) 
patients. For stem cell harvesting, a Fresenius 
apheresis device was used in 69 patients (40.8%), 
while a Haemonetics apheresis device was used in 
100 patients (59.2%). The median apheresis cycle 
for one mobilization period  applied to the patients 
was 3 days (range 1-4). Median WBC count at the 
first day of apheresis was 35800/μL (range 6900-
96500). Median peripheral blood CD34+ cell count 
at the first day of apheresis was 15/μL (range 0-
125). Median harvested total cell/kg was 11.43 x 108 
(range 1.94 x 108–26.30 x 108).Median CD34+ 
cell/kg count in the harvested product was 4.21 x 
106 (0.15 x 106–20.10 x 106). 
Statistical Analysis  
All continuous variables were dichotomized 
by use of median values as a cut-off value. 
Comparisons were made by chi square, Yates 
correction, and Fisher’s exact test appropriately, in 
univariate analysis. Time to apheresis was 
estimated as the time elapsed between the date of 
diagnosis and the date of apheresis. Variables with 
a p value <0.05 in univariate analysis were included 
into the multivariate analysis.  The multivariate 
analysis was done by logistic regression analysis 
with a method of backward selection. Statistical 
significance was accepted as the two-tailed p value 
as below 0.05. SPPS version 15.0 was used for the 
statistical analysis. 
RESULTS 
Gender and diagnosis, number of 
treatment lines before the apheresis procedure, time 
between diagnosis and apheresis, radiotherapy 
before the apheresis procedure, number of disease 
relapses before the apheresis and peripheral blood 
CD34+ cell count the first day of the apheresis 
procedure had no effect on harvested total cell/kg 
values. When the age of the patient was taken into 
account, it was observed that patients over the age 
of 50 have higher total cell/kg values (p=0.01). In 
patients having  >3 apheresis cycles, harvested total 
cell/kg value was higher (p=0.02). Apheresis device 
used was also analysed; harvested total cell/kg was 
found to be significantly higher with the Fresenius 
apheresis device than with the Haemonetics 
apheresis device (p:0.03). Peripheral blood WBC 
count at day 1 was associated with harvested total 
cell/kg (p=0.0003). When the effect of G-CSF used  
was analysed, the total harvested  cell/kg was 
significantly higher with Lenograstim over Filgrastim 
and this difference was statistically significant 
(p=0.0000005). (Table I).  
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Table I. Factors affecting Total cell/kg (Univariate Analysis) 
 
Total cell/kg ≤109 Total cell/kg >109 Variables―number (%) Number 
of 
Patients 
Number. (%) Number. (%) 
p  
Age (years) 139    
  <50 78 41 (52.6) 37 (47.4) 0.01 
  ≥50 61 19 (31.1) 42 (68.9)  
Sex 139    
  Male 80 35 (43.8) 45 (56.3) 0.9  
  Female 59 25 (42.4) 34 (57.6)  
Diagnosis  138    
  Multiple Myeloma 65 27 (41.5) 38 (58.5) 0.08  
  Acute Leukemia 11 8 (72.7) 3 (27.3)  
  Hodgkin’s Disease 31 15 (48.4) 16 (51.6)  
  Non-Hodgkin’s Lymphoma 31 9 (29.0) 22 (71.0)  
Number of relapses before apheresis 141    
  ≤1 128 59 (46.1) 69 (52.9) 0.7 
  >1 21 8 (38.1) 13 (61.9)  
Number of treatment lines before apheresis 150    
  ≤1 30 16 (53.3) 14 (46.7) 0.4 
  >1 120 51 (42.5) 69 (57.5)  
Radiotherapy before apheresis 139    
  Radiotherapy not treated 97 42 (43.3) 55 (56.7) 1.0 
  Radiotherapy treated 42 18 (42.9) 24 (57.1)  
Time to apheresis(months) 162    
  ≤12 74 40 (54.1) 34 (45.9) 0.2 
  >12 88 39 (44.3) 49 (55.7)  
G-CSF 162    
  Filgrastim 84 57 (67.9) 27 (22.1) 0.0000005 
  Lenograstim 78 22 (28.2) 56 (71.8)  
Apheresis Device 162    
  Fresenius® 65 25 (38.5) 40 (61.5) 0.03 
  Haemonetics® 97 54 (55.7) 43 (44.3)  
Number of apheresis cycles 162    
  ≤3 140 74 (52.9) 66 (47.1) 0.02 
  >3 22 5 (22.7) 17 (77.3)  
WBC (/μL) in 1st day of apheresis 162    
  <35000 73 47 (64.4) 26 (35.6) 0.0003 
  ≥35000 89 32 (36.0) 57 (64.0)  
CD34 (/μL) in 1st day of apheresis  158    
  ≤15 82 38 (46.3) 44 (53.7) 0.4 
  >15 76 40 (52.6) 36 (47.4)  
 
Harvested CD34+ cells/kg was not affected 
by the age or sex of the patient, radiation therapy 
before stem cell mobilization and the number of 
disease relapses before the apheresis procedure. 
When the diagnosis added into the comparison, the 
harvested CD34+ cell/kg was significantly higher in 
Hodgkin’s Disease, Multiple myeloma and Non-
Hodgkin’s lymphoma than acute leukemia 
respectively (p=0.005) In patients who received 
more than one treatment line before the apheresis 
procedure, harvested CD34+ cell/kg was 
prominently lower (p= 0.0004).  The harvested 
CD34+ cells was higher when time to apheresis was 
equal or less than 12 months and the number of 
apheresis cycles was equal or less than three 
(p=0.02 and p=0.000004). The relationship between 
peripheral blood WBC and CD34+ cell count at the 
first day of apheresis and the total harvested CD34+ 
cell/kg was statistically significant (p=0.0001,  
p:0=0005). A higher CD34+  cell was obtained when 
Filgrastim was used instead of Lenograstim during 
the mobilization procedure (p=0.000004). The 
Fresenius apheresis device harvested significantly 
more CD34+ cells than the Haemonetics apheresis 
device (p=0.007) (Table II). 
Achieving a total of ≥109 cell/kg was 
investigated using multivariate analysis. The most 
affecting factors was the number of apheresis cycles  
(more than three), mobilization with lenograstim, 
harvesting with the Fresenius apheresis device and 
WBC count ≥35.000 at 1st day of apheresis 
respectively. 
If the number of the apheresis cycle was 
more then three,  then the total cell/kg value was six 
times higher than in patients with less than three 
cycles (p:=0.02). Achieving a total cell/kg value over 
109 was 4 times more likely when the mobilization 
was done with lenograstim (p=0.0004). Achieving a 
total cell/kg value over 109 was 4 times more likely 
when harvesting was done with the Fresenius 
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device (p=0.001). If the WBC count at the first day 
of apheresis was equal or more than 35.000/μl, 
harvesting a total cell/kg value over 109 was 3 times 
more likely (p=0.00002)  (Table III).  
In multivariate analysis, diagnosis of the 
patient was the most important factor affecting total 
CD34+ cell/kg count. In non-Hodgkin’s lymphoma, 
multiple myeloma and Hodgkin’s Disease, the 
probability of harvesting a total CD34+ cell/kg count 
over 4x106 was 10, 15 and 17 times higher than 
acute leukemia (p=0.04; 0.01; 0.01), respectively. 
The probability of harvesting a total CD34+ cell/kg 
count over 4x106 was 2.5 times higher with 
Filgrastim mobilization (p=0.001). The probability of 
harvesting a total CD34+ cell/kg count over 4x106 
was 3 times higher when the apheresis was 
performed with the Fresenius device (p=0.03). If the 
WBC count at the 1st day of apheresis was  
≥35.000/μl, there was a 3 times higher probability 
for harvesting a total CD34+ cell/kg count over 
4x106 (p=0.006) (Table IV). 
 
 
Table II. Factors affecting CD34/kg (Univariate Analysis) 
 
CD34/kg      <4 x 
106 
CD34/kg      ≥4 x 
106 
Variables―Number (%) Number 
of 
Patients Number. (%) Number. (%) 
p  
Age (years) 142    
  <50 79 31 (39.2) 48 (60.8) 0.4 
  ≥50 63 29 (46.0) 34 (54.0)  
Sex 142    
  Male 80 33 (41.3) 47 (58.8) 0.8 
  Female 62 27 (43.5) 35 (56.5)  
Diagnosis 141    
  Multiple myeloma 67 22 (32.8) 45 (67.2) 0.005 
  Acute Keukemia 11 8 (72.7) 3 (27.3)  
  Hodgkin’s Disease 30 9 (30.0) 21 (70.0)  
  Non-Hodgkin’s Lymphoma 33 20 (60.6) 13 (39.4)  
Number of relapses before apheresis 155    
  ≤1 134 56 (41.8) 78 (58.2) 0.1 
  >1 21 13 (61.9) 8 (38.1)  
Number of treatment lines before apheresis 156    
  ≤1 32 5 (15.6) 27 (84.4) 0.0004 
  >1 124 65 (52.4) 59 (47.6)  
Radiotherapy before apheresis 142    
  Radiotherapy treated 100 47 (47.0) 53 (53.0) 0.1 
  Radiotherapy not treated 42 13 (31.0) 29 (69.0)  
Time to apheresis(months) 168    
  ≤12 78 28 (35.9) 50 (64.1) 0.02 
  >12 90 49 (54.4) 41 (45.6)  
G-CSF 168    
  Filgrastim 88 27 (30.7) 61 (69.3) 0.00004 
  Lenograstim 80 50 (62.5) 30 (37.5)  
Apheresis Device 169    
  Fresenius® 69 23 (33.3) 46 (66.7) 0.007 
  Haemonetics® 99 54 (54.5) 45 (44.5)  
Number of apheresis cycles 168    
  ≤3 147 57 (38.8) 90 (61.2) 0.000004 
  >3 21 20 (95.2) 1 (4.8)  
WBC (/μL) in 1st day of apheresis 168    
  <35000 78 48 (61.5) 30 (38.5) 0.0001 
  ≥35000 90 28 (32.2) 61 (67.8)  
CD34 (/μL) in 1st day of apheresis 164    
  ≤15 85 50 (58.8) 35 (41.2) 0.0005 
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Table III. Backwards selected logistic regression analysis of factors affecting the probability of total cell/kg ≥109 
 
%95 CI  Variable Coefficient(β) Standard 







Mobilization with Lenograstim  1.513 0.433 4.54  1.94 10.60 0.0004 
Harvesting with Fresenius 1.489 0.451 4.44 1.83 10.73 0.001 
Apheresis cycles >3  1.800 0.765 6.05 1.35 27.08 0.02 
WBC≥35000/μL at 1st day of 
apheresis 
1.227 0.426 3.41 1.48 7.86 0.00002 
OR= Odd Ratio         CI= Confidential Interval 
 
Table IV. Backwards selected logistic regression analysis of factors affecting the probability of CD34 cell/kg ≥4 x 106 
 
%95 CI  Variable Coefficient 
(β) 
Standard 







Mobilization with Filgrastim 1.704 0.516 2.41 0.91 6.38 0.001 
Harvesting with Fresenius 1.194 0.540 3.30 1.15 9.51 0.03 
WBC≥35000/μL at 1st day of 
apheresis 
1.372 0.501 3.94 1.48 10.52 0.006 
Diagnosis of Non-Hodgkin’s 
lymphoma 
2.324 1.112 10.21 1.16 90.31 0.04 
Diagnosis of multiple myeloma 2.719 1.064 15.17 1.89 121.97 0.01 
Diagnosis og Hodgkin’s Disease 2.864 1.133 17.54 1.91 161.48 0.01 
OR= Odd Ratio         CI= Confidential Interval 
 
DISCUSSION 
In this study, we found that important 
factors affecting total harvested cell/kg are, more 
than three apheresis cycles for an apheresis period, 
mobilization with lenograstim, harvesting with 
Fresenius device and ≥35.000 WBC count on the 
first day of apheresis. In addition, we found that 
important factors affecting total harvested CD34+ 
cell count are the diagnosis, peripheral blood WBC 
count on the first day of apheresis, harvesting with 
Fresenius device and mobilization with Filgrastim. 
In achieving the highest total CD34+ cell 
collection, we found that the most important variable 
is the patient’s diagnosis. We found that the rate of 
successful CD34+ cell collection was highest in 
Hodgkin’s Disease, followed by multiple myeloma. 
The lowest rate was found in acute leukemias. We 
observed that in multiple myeloma and Hodgkin’s 
Disease patients, the probability of CD34+ cell count 
for being ≥ 4x106 was 15 and 17 times higher than 
in acute leukemia patients, respectively. It seems 
that the impact of high stem cell damage caused by 
salvage treatments used in acute leukemia 
adversely affects the CD34+ cell mobilization. This 
result is consistent with previous studies4-8. 
There are several studies reporting the 
effect of peripheral blood WBC and CD34+ cell 
count on the success of mobilization at first day 
apheresis9-18. In our study, we found that there is a 
significant relationship between peripheral blood 
WBC and CD34+ cell count and mobilized total 
CD34+ cells/kg. However, in multivariate analysis 
the effect of peripheral blood CD34+ cell count at 
first day of apheresis on collected CD34+ cell/kg 
was abolished, whereas the effect of the  peripheral 
blood WBC count was maintained. 
The effectiveness of the apheresis device 
seems to have an influence on the harvested 
CD34+ cell/kg count. Previous studies compared 
the efficiency of different apheresis devices on stem 
cell collection. But the number of studies comparing 
both devices (Fresenius AS 104 and Haemonetics 
MCS 3P devices) are limited19. In one of these 
studies,20 it has been suggested that a higher 
number of CD34+ cells can be harvested with 
Fresenius AS104 in pediatric populations. Our 
results are in line with these findings and suggest 
that a higher number of total cell/kg or total CD34+ 
cell/kg can be harvested with Fresenius AS104 in 
comparison to Haemonetics MCS 3P.  
Stem cell apheresis is performed using G-
CSF (filgrastim and lenograstim) at our institution. 
The chemical and  physicochemical structures of 
these two molecules differ. Lenograstim is a 
glycosylated molecule and this property makes it 
more stable to pH, temperature and proteolysis 
effects21. Previous in-vitro studies suggest that 
Lenograstim is more potent than filgrastim22-24. But 
these studies evaluated the mobilization capacities 
of these agents, and the superiority of lenograstim is 
shown on healthy donors25,26 not on patient groups 
with the exception of limited studies27. In our study, 
a total of 169 apheresis  procedures were performed 
and 89 (52.7%) mobilizations were done with 
filgrastim, and 80 (47.3%) were done with 
lenograstim. We found that the total harvested 
Marmara Medical Journal 2011; 24 (1):31-37 
I. KAYGUSUZ, et al  
Factors affecting stem cell mobilization 
 36 
cell/kg was higher with lenograstim and mobilization 
with lenograstim was 4 times stronger in collection 
over 109 total cell/kg cells. But when CD34+ cell 
counts were analysed, the achieved CD34+ cell 
numbers were higher with filgrastim and after 
mobilization with filgrastim,  collections of cells over 
4x106 total CD34+ cell/kg were 2.5 times more likely 
than that with lenograstim. Lenograstim was found 
to be more efficient in terms of increasing the total 
cell/kg values but was inferior to filgrastim in the 
mobilization of CD34+ cells. This finding may point 
out that filgrastim is more successful in mobilizing 
progenitor cells than lenograstim which in turn may 
provide mobilization of more mature cells to the 
peripheral blood. It is important to consider this 
finding, during the mobilization procedure especially 
in patients with poor stem cell reserve.  
In addition, our findings suggest that, age, 
gender, radiation therapy before stem cell 
mobilization and number of disease relapses before 
the apheresis procedure do not have any influence 
on harvested CD34+ cells/kg. The negative effect of 
radiotherapy on stem cell mobilization has been 
reported previously in various studies28,29. In our 
study, receiving radiotherapy before the apheresis 
procedure did not affect harvested total cell/kg or 
CD34+ cell/kg negatively. Dose, duration, 
application fields and magnitude of radiotherapy 
may modify the stem cell damaging effects of 
radiation. Our finding of a higher yield of collected 
CD34+ cell count in patients treated with the 
apheresis procedure up to 12 months after the 
diagnosis is in line with certain previous studies but 
when analysed with multivariate analysis methods, 
the effect of time from diagnosis to apheresis 
disappeared. İn multivariate analysis, the negative 
effect of multiple treatment lines before the 
apheresis procedure on the harvested CD34+ 
cell/kg cell count disappeared, also.  
In conclusion, we report that, diagnosis of 
the patient, mobilization with filgrastim, mobilization 
with Fresenius apheresis device and peripheral 
blood leukocyte count at the first day of apheresis 
are variables affecting peripheral stem cell 
mobilization. We suggest that taking these factors 
into account before stem cell apheresis may lead to 
a more appropriate decision making in the selection 
of mobilization agents and apheresis devices, which 
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